<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846208</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 04-1271</org_study_id>
    <secondary_id>U19AI066738</secondary_id>
    <secondary_id>CoFAR7</secondary_id>
    <nct_id>NCT01846208</nct_id>
  </id_info>
  <brief_title>Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy</brief_title>
  <acronym>CoFAR7</acronym>
  <official_title>Oral Desensitization to Egg With Subsequent Induction of Sustained Unresponsiveness for Egg-Allergic Children Using Baked Egg or Egg Oral Immunotherapy (OIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugh A Sampson, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consortium of Food Allergy Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Baked Egg vs. Egg Oral Immunotherapy for inducing
      sustained unresponsiveness to egg exposure in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Food allergy affects 6-8 percent of children in the United States. In young children,
      reactions to egg can range from hives to severe life threatening allergic reactions called
      anaphylaxis. Current treatment for food allergy is complete avoidance of the food and to
      carry antihistamines and self-injectable epinephrine if an accidental reaction occurs.
      However, accidental exposure to allergens in processed foods may be difficult to avoid.
      Currently, several therapeutic strategies are being investigated to prevent and treat food
      allergies. Since immunotherapy injections for food allergy are associated with a high rate of
      allergic reactions, alternate approaches to treatment are needed. Oral (by mouth)
      immunotherapy (OIT) is one approach that has been tried in some studies in the treatment of
      food allergies. The purpose of this study is to compare baked foods with egg versus (vs.) egg
      OIT. The intent of the study is to investigate if participants will be able to consume egg
      after taking baked foods with egg or egg OIT for a period of time and then stopping for a
      certain period. This is referred to as tolerance or sustained unresponsiveness. This study
      will evaluate the effectiveness of the egg OIT vs. baked egg by having each participant
      ingest egg white solid or baked foods with egg. This will be done over 2 years.

      This study will last 2 years. All eligible subjects will receive a baked egg oral food
      challenge (OFC). Those who pass the baked egg OFC will then have a 2 gm egg OFC. Those who
      react to the egg OFC will be randomized to Baked Egg or Egg OIT. Individuals who do not pass
      the initial baked egg OFC will be assigned to Egg OIT. Those who pass the egg OFC will not be
      eligible for the study and will be followed per site standard of care. All eligible and
      enrolled subjects will have a 1-year and a 2-year OFC.

      At selected visits, blood and urine collection, physical examination, prick skin tests, and
      atopic dermatitis and asthma evaluations will occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Unresponsiveness to Egg Consumption at 2 Years.</measure>
    <time_frame>2 Years</time_frame>
    <description>Sustained unresponsiveness - able to successfully consume 7444 mg egg white protein in a desensitization OFC and, after an 8-10 week egg-free interval, were also able to successfully consume 7444 mg egg white protein in an OFC after up to 2 years of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Desensitization to &gt;= 4.444 Grams Egg White Solid.</measure>
    <time_frame>1 Year and 2 Years</time_frame>
    <description>Development of desensitization to able to successfully consume &gt;=4444 mg egg white protein during a desensitization OFC on therapy at 1 year and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Serious Adverse Events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Incidence of all serious adverse events during the study.
No statistical analyses were performed since there were no events in 2 of the 3 treatment groups and only 1 event in the third so it would not be meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unrestricted Consumption of Unbaked Egg</measure>
    <time_frame>3 years after randomization</time_frame>
    <description>Number of participants who reported consumption of concentrated (unbaked) egg in their diet on the long-term follow-up questionnaire 3 years after randomization, indicating unrestricted consumption of unbaked egg. This is a qualitative questionnaire asking participants about egg in their diet, symptoms, and what treatment they received for their allergic reactions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Egg-specific Mechanistic Measures and Skin Prick Test Results.</measure>
    <time_frame>2 Years</time_frame>
    <description>Changes in egg-specific IgE and IgG4, changes in SPT mean wheal diameters, basophil reactivity, Th2 and Treg values.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Egg OIT Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baked Egg Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egg OIT Assigned</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Egg Oral Immunotherapy</intervention_name>
    <description>Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
    <arm_group_label>Egg OIT Assigned</arm_group_label>
    <arm_group_label>Egg OIT Randomized</arm_group_label>
    <other_name>Egg white solid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baked Egg</intervention_name>
    <description>Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
    <arm_group_label>Baked Egg Randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 3 through 16 years with a serum IgE to egg of &gt;= 5 kUA/L within the past 12
             months]

          -  Reacting to the initial baked egg OFC with dose limiting symptoms OR

          -  Reacting on a 2 gm egg OFC with dose limiting symptoms to a cumulative dose of 2 gm or
             less after passing the initial baked egg OFC

          -  Written informed consent from subject and/or parent/guardian

          -  Written assent from all subjects as appropriate

          -  All females of child bearing age must be using appropriate birth control

        Exclusion Criteria:

          -  History of anaphylaxis to egg resulting in hypotension, neurological compromise or
             mechanical ventilation

          -  Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy
             (e.g., heart disease, diabetes)

          -  Active eosinophilic gastrointestinal disease in the past 2 years

          -  Participation in any interventional study for the treatment of food allergy in the
             past 6 months

          -  Subject is on &quot;build-up phase&quot; of immunotherapy (i.e., has not reached maintenance
             dosing). Subjects tolerating maintenance allergen immunotherapy can be enrolled.

          -  Severe asthma, or uncontrolled mild or moderate asthma. More information on these
             exclusion criteria can be found in the protocol.

          -  Inability to discontinue antihistamines for initial day escalation, skin testing or
             OFC

          -  Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral
             or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic
             therapy (e.g. infliximab, rituximab, etc.) within the past year

          -  Use of Beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors,
             angiotensin-receptor blockers (ARB) or calcium channel blockers

          -  Use of investigational drug within 90 days or plan to use investigational drug during
             the study period

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh A Sampson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cofargroup.org</url>
    <description>Study Web Site</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 30, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>September 24, 2018</results_first_submitted>
  <results_first_submitted_qc>October 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>July 14, 2019</last_update_submitted>
  <last_update_submitted_qc>July 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Hugh A Sampson, MD</investigator_full_name>
    <investigator_title>Director, Jaffe Food Allergy Institute</investigator_title>
  </responsible_party>
  <keyword>Egg Allergy</keyword>
  <keyword>Egg Oral Immunotherapy</keyword>
  <keyword>Food Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT01846208/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT01846208/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study recruitment began in July 2013 and accrual closed in August 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Baked Egg Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
        </group>
        <group group_id="P2">
          <title>Egg OIT Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
        <group group_id="P3">
          <title>Egg OIT Assigned</title>
          <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiatiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 1 Desensitization OFC</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 2 Desensitization OFC</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 2 Sustained Unresponsiveness OFC</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dosing Symptoms</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Developed Eosinophilic Esophagitis (EoE)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused SU OFC</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only treated participants are included in analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Baked Egg Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
        </group>
        <group group_id="B2">
          <title>Egg OIT Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
        <group group_id="B3">
          <title>Egg OIT Assigned</title>
          <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="3.0"/>
                    <measurement group_id="B2" value="9.1" spread="3.1"/>
                    <measurement group_id="B3" value="8.8" spread="2.4"/>
                    <measurement group_id="B4" value="8.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Non-Hispanic or Non-Latino origin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino origin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other Food Allergy History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No/Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Severity History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No History</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild intermittent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild persistent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate persistent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergic GI Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergic Rhinitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atopic Dermatitis History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atopic Dermatitis Score</title>
          <description>The Atopic Dermatitis Total Score is scored on a 10 point scale of 0 to 9 where a higher score indicates increasing severity of atopic dermatitis. This score is a combination of three scores that range from 0 to 3 in the following areas: body surface area score, disease course, and disease intensity.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" lower_limit="0" upper_limit="5.0"/>
                    <measurement group_id="B2" value="0.0" lower_limit="0" upper_limit="5.0"/>
                    <measurement group_id="B3" value="0.0" lower_limit="0" upper_limit="4.0"/>
                    <measurement group_id="B4" value="0.0" lower_limit="0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Egg IgE</title>
          <description>Assay limits of detection Ranges: 0.01 to 100 kUA/L, Values outside of range were truncated (lower and upper values): 0.05 and 101 kUA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>kUA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.77" lower_limit="6.54" upper_limit="27.10"/>
                    <measurement group_id="B2" value="12.30" lower_limit="9.09" upper_limit="31.10"/>
                    <measurement group_id="B3" value="26.25" lower_limit="11.7" upper_limit="68.80"/>
                    <measurement group_id="B4" value="15.60" lower_limit="8.22" upper_limit="37.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Total IgE</title>
          <description>Assay limits of detection ranges: Total IgE: 5000 kU/L upper limit, Values above range were truncated: 5001 kU/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>kUA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="809.00" lower_limit="389.00" upper_limit="1870.00"/>
                    <measurement group_id="B2" value="873.00" lower_limit="269.00" upper_limit="1671.00"/>
                    <measurement group_id="B3" value="960.00" lower_limit="390.00" upper_limit="1659.00"/>
                    <measurement group_id="B4" value="885.50" lower_limit="366.50" upper_limit="1699.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Egg IgG4</title>
          <description>Assay limits of detection ranges: 0.07 to 30 mgA/L, Values outside of range were truncated (lower and upper values): 0.035 and 31 mgA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>mgA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.84" lower_limit="0.08" upper_limit="7.31"/>
                    <measurement group_id="B2" value="0.81" lower_limit="0.26" upper_limit="3.71"/>
                    <measurement group_id="B3" value="0.28" lower_limit="0.13" upper_limit="1.02"/>
                    <measurement group_id="B4" value="0.64" lower_limit="0.17" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Egg %IgE</title>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>% IgE</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.86" lower_limit="0.89" upper_limit="3.62"/>
                    <measurement group_id="B2" value="1.80" lower_limit="0.97" upper_limit="5.29"/>
                    <measurement group_id="B3" value="3.06" lower_limit="1.21" upper_limit="5.86"/>
                    <measurement group_id="B4" value="2.13" lower_limit="1.03" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ratio IgG4/IgE</title>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.94" lower_limit="2.23" upper_limit="119.64"/>
                    <measurement group_id="B2" value="25.75" lower_limit="11.13" upper_limit="86.55"/>
                    <measurement group_id="B3" value="5.01" lower_limit="2.79" upper_limit="11.24"/>
                    <measurement group_id="B4" value="11.18" lower_limit="3.86" upper_limit="42.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ovalbumin IgE</title>
          <description>Assay limits of detection ranges: 0.01 to 100 kUA/L, Values outside of range were truncated (lower and upper values): 0.05 and 101 kUA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>kUA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.53" lower_limit="3.20" upper_limit="20.20"/>
                    <measurement group_id="B2" value="5.85" lower_limit="3.41" upper_limit="10.40"/>
                    <measurement group_id="B3" value="16.10" lower_limit="7.30" upper_limit="29.70"/>
                    <measurement group_id="B4" value="8.88" lower_limit="4.11" upper_limit="20.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ovomucoid IgE</title>
          <description>Assay limits of detection ranges: 0.01 to 100 kUA/L, Values outside of range were truncated (lower and upper values): 0.05 and 101 kUA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>kUA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.94" lower_limit="1.52" upper_limit="13.40"/>
                    <measurement group_id="B2" value="6.93" lower_limit="3.27" upper_limit="13.20"/>
                    <measurement group_id="B3" value="16.40" lower_limit="6.11" upper_limit="35.50"/>
                    <measurement group_id="B4" value="9.76" lower_limit="3.48" upper_limit="18.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ovalbumin IgG4</title>
          <description>Assay limits of detection ranges: 0.07 to 30 mgA/L, Values outside of range were truncated (lower and upper values): 0.035 and 31 mgA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>mgA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.64" lower_limit="0.14" upper_limit="5.23"/>
                    <measurement group_id="B2" value="0.53" lower_limit="0.09" upper_limit="1.93"/>
                    <measurement group_id="B3" value="0.33" lower_limit="0.16" upper_limit="1.04"/>
                    <measurement group_id="B4" value="0.49" lower_limit="0.14" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ovomucoid IgG4</title>
          <description>Assay limits of detection ranges: 0.07 to 30 mgA/L, Values outside of range were truncated (lower and upper values): 0.035 and 31 mgA/L</description>
          <population>One participant in Egg OIT Assigned arm had no plasma</population>
          <units>mgA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.25" lower_limit="0.04" upper_limit="1.34"/>
                    <measurement group_id="B2" value="0.15" lower_limit="0.04" upper_limit="2.49"/>
                    <measurement group_id="B3" value="0.09" lower_limit="0.04" upper_limit="0.26"/>
                    <measurement group_id="B4" value="0.11" lower_limit="0.04" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Egg Skin Prick Test (SPT)</title>
          <description>Skin prick tests performed using study approved procedures for food and environmental allergens. A skin test probe is pressed through a commercial extract of an allergen into the epidermis.</description>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.50" lower_limit="5.50" upper_limit="13.50"/>
                    <measurement group_id="B2" value="11.00" lower_limit="6.50" upper_limit="15.00"/>
                    <measurement group_id="B3" value="12.00" lower_limit="7.50" upper_limit="16.50"/>
                    <measurement group_id="B4" value="11.00" lower_limit="6.50" upper_limit="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Milk SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.00" lower_limit="0" upper_limit="10.00"/>
                    <measurement group_id="B2" value="3.00" lower_limit="0" upper_limit="8.50"/>
                    <measurement group_id="B3" value="3.50" lower_limit="0" upper_limit="44.00"/>
                    <measurement group_id="B4" value="2.50" lower_limit="0" upper_limit="44.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Peanut SPT</title>
          <population>One Egg OIT Assigned subject refused to complete the peanut SPT at baseline</population>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.50" lower_limit="3.50" upper_limit="17.00"/>
                    <measurement group_id="B2" value="11.00" lower_limit="8.50" upper_limit="17.50"/>
                    <measurement group_id="B3" value="10.50" lower_limit="1.75" upper_limit="21.00"/>
                    <measurement group_id="B4" value="11.00" lower_limit="3.25" upper_limit="17.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Tree SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.50" lower_limit="0" upper_limit="7.00"/>
                    <measurement group_id="B2" value="4.50" lower_limit="0" upper_limit="8.50"/>
                    <measurement group_id="B3" value="3.00" lower_limit="0" upper_limit="6.50"/>
                    <measurement group_id="B4" value="3.50" lower_limit="0" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Grass SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.50" lower_limit="0" upper_limit="7.00"/>
                    <measurement group_id="B2" value="0.00" lower_limit="0" upper_limit="6.50"/>
                    <measurement group_id="B3" value="2.50" lower_limit="0" upper_limit="6.50"/>
                    <measurement group_id="B4" value="2.50" lower_limit="0" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Weed SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.50" lower_limit="0" upper_limit="5.50"/>
                    <measurement group_id="B2" value="0.00" lower_limit="0" upper_limit="3.50"/>
                    <measurement group_id="B3" value="0.00" lower_limit="0" upper_limit="3.50"/>
                    <measurement group_id="B4" value="0.00" lower_limit="0" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Mold SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.50" lower_limit="0" upper_limit="4.00"/>
                    <measurement group_id="B2" value="1.00" lower_limit="0" upper_limit="4.50"/>
                    <measurement group_id="B3" value="0.00" lower_limit="0" upper_limit="3.50"/>
                    <measurement group_id="B4" value="0.00" lower_limit="0" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cockroach SPT</title>
          <units>mms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="39"/>
                    <count group_id="B4" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.00" lower_limit="0" upper_limit="1.50"/>
                    <measurement group_id="B2" value="0.00" lower_limit="0" upper_limit="3.00"/>
                    <measurement group_id="B3" value="0.00" lower_limit="0" upper_limit="2.50"/>
                    <measurement group_id="B4" value="0.00" lower_limit="0" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Unresponsiveness to Egg Consumption at 2 Years.</title>
        <description>Sustained unresponsiveness - able to successfully consume 7444 mg egg white protein in a desensitization OFC and, after an 8-10 week egg-free interval, were also able to successfully consume 7444 mg egg white protein in an OFC after up to 2 years of therapy.</description>
        <time_frame>2 Years</time_frame>
        <population>All treated participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baked Egg Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
          </group>
          <group group_id="O2">
            <title>Egg OIT Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
          <group group_id="O3">
            <title>Egg OIT Assigned</title>
            <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Unresponsiveness to Egg Consumption at 2 Years.</title>
          <description>Sustained unresponsiveness - able to successfully consume 7444 mg egg white protein in a desensitization OFC and, after an 8-10 week egg-free interval, were also able to successfully consume 7444 mg egg white protein in an OFC after up to 2 years of therapy.</description>
          <population>All treated participants were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>% participants passed Year 2 SU OFC: Baked vs. Egg OIT-Randomized</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>32.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>55.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>% participants passed Year 2 SU OFC: Egg OIT-Randomized vs. Egg OIT-Assigned</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>25.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>49.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desensitization to &gt;= 4.444 Grams Egg White Solid.</title>
        <description>Development of desensitization to able to successfully consume &gt;=4444 mg egg white protein during a desensitization OFC on therapy at 1 year and 2 years.</description>
        <time_frame>1 Year and 2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baked Egg Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
          </group>
          <group group_id="O2">
            <title>Egg OIT Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
          <group group_id="O3">
            <title>Egg OIT Assigned</title>
            <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Desensitization to &gt;= 4.444 Grams Egg White Solid.</title>
          <description>Development of desensitization to able to successfully consume &gt;=4444 mg egg white protein during a desensitization OFC on therapy at 1 year and 2 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desensitized Success at Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Desensitized Success at Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>% participants desensitized to &gt;=4444 mg at Year 2 OFC: Baked vs. Egg OIT-Randomized</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>64.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.9</ci_lower_limit>
            <ci_upper_limit>85.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>% participants desensitized to &gt;=4444 mg at Year 2 OFC: Egg OIT-Randomized vs. Egg OIT-Assigned</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>37.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>% participants desensitized to &gt;=4444 mg at Year 1 OFC: Baked vs. Egg OIT-Randomized</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>44.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.4</ci_lower_limit>
            <ci_upper_limit>69.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>% participants desensitized to &gt;=4444 mg at Year 1 OFC: Egg OIT-Randomized vs. Egg OIT-Assigned</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>41.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Serious Adverse Events</title>
        <description>Incidence of all serious adverse events during the study.
No statistical analyses were performed since there were no events in 2 of the 3 treatment groups and only 1 event in the third so it would not be meaningful.</description>
        <time_frame>up to 3 years</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Baked Egg Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
          </group>
          <group group_id="O2">
            <title>Egg OIT Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
          <group group_id="O3">
            <title>Egg OIT Assigned</title>
            <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Serious Adverse Events</title>
          <description>Incidence of all serious adverse events during the study.
No statistical analyses were performed since there were no events in 2 of the 3 treatment groups and only 1 event in the third so it would not be meaningful.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unrestricted Consumption of Unbaked Egg</title>
        <description>Number of participants who reported consumption of concentrated (unbaked) egg in their diet on the long-term follow-up questionnaire 3 years after randomization, indicating unrestricted consumption of unbaked egg. This is a qualitative questionnaire asking participants about egg in their diet, symptoms, and what treatment they received for their allergic reactions.</description>
        <time_frame>3 years after randomization</time_frame>
        <population>Participants who completed the long term follow-up questionnaire 3 years after randomization are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Baked Egg Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
          </group>
          <group group_id="O2">
            <title>Egg OIT Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
          <group group_id="O3">
            <title>Egg OIT Assigned</title>
            <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unrestricted Consumption of Unbaked Egg</title>
          <description>Number of participants who reported consumption of concentrated (unbaked) egg in their diet on the long-term follow-up questionnaire 3 years after randomization, indicating unrestricted consumption of unbaked egg. This is a qualitative questionnaire asking participants about egg in their diet, symptoms, and what treatment they received for their allergic reactions.</description>
          <population>Participants who completed the long term follow-up questionnaire 3 years after randomization are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>% participants with unrestricted consumption of unbaked (concentrated) egg 3 years after randomization: Baked vs. Egg OIT-Randomized</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-50.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.4</ci_lower_limit>
            <ci_upper_limit>-21.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>% participants with unrestricted consumption of unbaked (concentrated) egg 3 years after randomization: Egg OIT-Randomized vs. Egg OIT-Assigned</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Barnard's Exact Test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>60.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Egg-specific Mechanistic Measures and Skin Prick Test Results.</title>
        <description>Changes in egg-specific IgE and IgG4, changes in SPT mean wheal diameters, basophil reactivity, Th2 and Treg values.</description>
        <time_frame>2 Years</time_frame>
        <population>Data not reported because these are for tertiary objectives that are exploratory.</population>
        <group_list>
          <group group_id="O1">
            <title>Baked Egg Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
          </group>
          <group group_id="O2">
            <title>Egg OIT Randomized</title>
            <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
          <group group_id="O3">
            <title>Egg OIT Assigned</title>
            <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Egg-specific Mechanistic Measures and Skin Prick Test Results.</title>
          <description>Changes in egg-specific IgE and IgG4, changes in SPT mean wheal diameters, basophil reactivity, Th2 and Treg values.</description>
          <population>Data not reported because these are for tertiary objectives that are exploratory.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 3 years, through last clinic visit.</time_frame>
      <desc>* Unsolicited - collected by non-systematic assessment
+ Solicited (dosing symptoms from daily logs) - collected by systematic assessment</desc>
      <group_list>
        <group group_id="E1">
          <title>Baked Egg Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and &quot;safe&quot; commercial products with up to four oral food challenges as directed by the protocol.
Baked Egg: Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.</description>
        </group>
        <group group_id="E2">
          <title>Egg OIT Randomized</title>
          <description>Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
        <group group_id="E3">
          <title>Egg OIT Assigned</title>
          <description>Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
Egg Oral Immunotherapy: Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (21.1)">Ear pain+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="41" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E2" events="244" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E3" events="2030" subjects_affected="31" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="37" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Diarrhoea+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="15" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspepsia+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="22" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Flatulence+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="49" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Lip swelling+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Nausea+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="28" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Oral discomfort+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral disorder+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="269" subjects_affected="19" subjects_at_risk="27"/>
                <counts group_id="E2" events="487" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E3" events="895" subjects_affected="36" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Tongue pruritus+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting*</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="20" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" events="62" subjects_affected="20" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (21.1)">Chest discomfort+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="16" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza like illness*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Malaise+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia*</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E3" events="22" subjects_affected="12" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (21.1)">Allergy to animal*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypersensitivity*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis*</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cellulitis*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Croup infectious*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ear infection*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Febrile infection*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral*</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis*</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection*</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lice infestation*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localised infection*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Otitis media*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal*</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis*</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Upper respiratory tract infection*</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Viral infection*</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection*</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache*</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Headache+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="16" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma*</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough*</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" events="39" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="390" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal pruritus+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (18.1)">Oropharyngeal discomfort+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="39" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="166" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E3" events="394" subjects_affected="24" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain*</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Sneezing+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="59" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Throat irritation+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="19" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="18" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic*</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eczema*</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Eczema+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="24" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Pruritus+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="30" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="22" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="368" subjects_affected="20" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash papular*</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash*</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Rash+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="182" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="29" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (21.1)">Urticaria+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="31" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" events="107" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" events="58" subjects_affected="17" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing+</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="24" subjects_affected="10" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hugh A. Sampson</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9426</phone>
      <email>hugh.sampson@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

